MA32970B1 - Analogues du glucagon - Google Patents

Analogues du glucagon

Info

Publication number
MA32970B1
MA32970B1 MA34020A MA34020A MA32970B1 MA 32970 B1 MA32970 B1 MA 32970B1 MA 34020 A MA34020 A MA 34020A MA 34020 A MA34020 A MA 34020A MA 32970 B1 MA32970 B1 MA 32970B1
Authority
MA
Morocco
Prior art keywords
glucagon
methods
present
isotope
peptides
Prior art date
Application number
MA34020A
Other languages
Arabic (ar)
English (en)
Inventor
Eddi Meier
Ditte Riber
Marie Skovgaard
Bjarne Due Larsen
Jens Rosengren Daugaard
Original Assignee
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma As filed Critical Zealand Pharma As
Publication of MA32970B1 publication Critical patent/MA32970B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)

Abstract

L'invention concerne des matériaux et des méthodes pour faciliter la perte de poids ou empêcher la prise de poids, et traiter le diabète, le syndrome métabolique et les troubles associés. L'invention concerne, en particulier de nouveaux peptides analogues du glucagon efficaces dans ces méthodes. Les peptides peuvent médier leur effet par leur sélectivité accrue pour le récepteur du GLP-1 par rapport au glucagon humain.
MA34020A 2008-12-15 2008-12-15 Analogues du glucagon MA32970B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/GB2008/004121 WO2010070251A1 (fr) 2008-12-15 2008-12-15 Analogues du glucagon

Publications (1)

Publication Number Publication Date
MA32970B1 true MA32970B1 (fr) 2012-01-02

Family

ID=40428061

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34020A MA32970B1 (fr) 2008-12-15 2008-12-15 Analogues du glucagon

Country Status (19)

Country Link
US (2) US8685919B2 (fr)
EP (2) EP2370459A1 (fr)
JP (1) JP5635529B2 (fr)
KR (2) KR20150116912A (fr)
CN (1) CN102282167B (fr)
AP (1) AP2011005774A0 (fr)
AU (1) AU2008365555B2 (fr)
BR (1) BRPI0823378A2 (fr)
CA (1) CA2747109A1 (fr)
EA (1) EA020537B1 (fr)
HK (1) HK1203531A1 (fr)
IL (1) IL213477A0 (fr)
MA (1) MA32970B1 (fr)
MX (1) MX2011006313A (fr)
MY (1) MY160219A (fr)
SG (1) SG172170A1 (fr)
TN (1) TN2011000295A1 (fr)
UA (1) UA104605C2 (fr)
WO (1) WO2010070251A1 (fr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101200227B1 (ko) 2005-05-04 2012-11-13 질랜드 파마 에이/에스 글루카곤 유사 펩티드-2(ｇｌｐ-2) 유사체
NZ576260A (en) 2006-11-08 2012-04-27 Zealand Pharma As GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES comprising one of more substitutions as compared to h[Gly2]GLP-2
WO2010070255A1 (fr) 2008-12-15 2010-06-24 Zealand Pharma A/S Analogues du glucagon
JP5635531B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
CN102292347A (zh) 2008-12-15 2011-12-21 西兰制药公司 胰高血糖素类似物
ME02220B (me) 2009-07-13 2016-02-20 Zealand Pharma As Analozi acilovanog glukagona
CN107129538B (zh) 2010-04-27 2021-07-16 西兰制药公司 Glp-1受体激动剂和胃泌素的肽缀合物及其用途
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
BR112012033225A2 (pt) * 2010-06-24 2017-06-20 Zealand Pharma As análogos do glucagon
MA34913B1 (fr) * 2011-01-20 2014-02-01 Zealand Pharma As Combinaison d'analogues du glucagon acylé à des analogues d'insuline
CA2849673A1 (fr) 2011-09-23 2013-03-28 Novo Nordisk A/S Nouveaux analogues du glucagon
WO2013064669A1 (fr) 2011-11-03 2013-05-10 Zealand Pharma A/S Conjugués de peptide agoniste du récepteur du glp-1 et de gastrine
CA2872315A1 (fr) 2012-05-03 2013-11-07 Zealand Pharma A/S Analogues du glucagon-like peptide 2 (glp-2)
US10100097B2 (en) 2012-05-03 2018-10-16 Zealand Pharma A/S GIP-GLP-1 dual agonist compounds and methods
EP2664374A1 (fr) * 2012-05-15 2013-11-20 F. Hoffmann-La Roche AG Dérivés de dipeptide d'acide lysine-glutamique
CN104583234A (zh) 2012-06-14 2015-04-29 赛诺菲 毒蜥外泌肽-4肽类似物
CN104662038B (zh) 2012-07-23 2018-11-06 西兰制药公司 胰高血糖素类似物
TWI608013B (zh) * 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
AR092873A1 (es) 2012-09-26 2015-05-06 Cadila Healthcare Ltd Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
BR112015014510A2 (pt) 2012-12-21 2017-11-21 Sanofi Sa agonistas de glp1/gip duais ou de glp1/gip/glucagon trigonais
MX365465B (es) 2013-03-21 2019-06-04 Sanofi Aventis Deutschland Sintesis de productos peptidicos que contienen imida ciclica.
SG11201506804VA (en) 2013-03-21 2015-09-29 Sanofi Aventis Deutschland Synthesis of hydantoin containing peptide products
AR095986A1 (es) 2013-04-03 2015-11-25 Sanofi Sa Proteínas modificadas que regulan glucosa en sangre con perfil alterado de actividad farmacológica y preparación de las mismas
KR20160021758A (ko) 2013-04-18 2016-02-26 노보 노르디스크 에이/에스 의학용으로 사용하기 위한 안정하고 연장된 glp-1/글루카곤 수용체 코-아고니스트
GB201315335D0 (en) * 2013-08-29 2013-10-09 Of Singapore Amino diacids containing peptide modifiers
CN105745222A (zh) 2013-10-17 2016-07-06 西兰制药公司 酰化胰高血糖素类似物
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
CA2929107C (fr) * 2013-11-06 2023-09-26 Zealand Pharma A/S Composes agonistes triples glucagon-glp-1-gip
TWI670281B (zh) * 2013-11-06 2019-09-01 西蘭製藥公司 Ｇｉｐ－ｇｌｐ－１雙重促效劑化合物及方法
WO2015086731A1 (fr) 2013-12-13 2015-06-18 Sanofi Analogues peptidiques de l'exendine-4 en tant qu'agonistes mixtes des récepteurs glp-1/glucagon
EP3080149A1 (fr) 2013-12-13 2016-10-19 Sanofi Agonistes mixtes des récepteurs du glp-1/glucagon
WO2015086730A1 (fr) 2013-12-13 2015-06-18 Sanofi Analogues peptidiques de l'exendine 4 non acylés
WO2015086729A1 (fr) 2013-12-13 2015-06-18 Sanofi Agonistes mixtes des récepteurs glp-1/gip
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
ES2883345T3 (es) 2014-10-29 2021-12-07 Zealand Pharma As Compuestos agonistas del GIP y métodos
MY175669A (en) 2015-02-17 2020-07-03 Lilly Co Eli Nasal powder formulation for treatment of hypoglycemia
TWI748945B (zh) * 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
MX2017011182A (es) 2015-03-18 2018-06-06 Zealand Pharma As Analogos de amilina.
WO2016168388A2 (fr) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Thérapies pour l'obésité, le diabète et indications associées
JP6989385B2 (ja) 2015-04-16 2022-01-05 ジーランド ファーマ アクティーゼルスカブ アシル化グルカゴン類似体
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198628A1 (fr) 2015-06-12 2016-12-15 Sanofi Dérivés d'exendine-4 non-acylée comme agonistes doubles du récepteur glp -1/glucagon
WO2016198624A1 (fr) 2015-06-12 2016-12-15 Sanofi Dérivés d'exendine 4 utilisés en tant qu'agonistes trigonaux des récepteurs du glp-1/glucagon/gip
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
LT3494120T (lt) 2016-08-05 2021-05-25 Boehringer Ingelheim International Gmbh Oksadiazolopiridino dariniai, skirti naudoti kaip grelino o-aciltransferazės (goat) inhibitoriai
US10071140B2 (en) 2016-09-09 2018-09-11 Zealand Pharma A/S Amylin analogues
TW201832783A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 包含ｇｌｐ－１／胰高血糖素雙重激動劑、連接子和透明質酸的接合物
BR112019010624A2 (pt) 2016-12-09 2019-10-22 Zealand Pharma As agonistas duplos de glp-1/glp-2 acilados e composição
WO2018103868A1 (fr) * 2016-12-09 2018-06-14 Zealand Pharma A/S Agonistes doubles de glp-1/glp-2 acylés
EP3746449B1 (fr) 2018-02-02 2022-03-30 Boehringer Ingelheim International GmbH Dérivés d'oxadiazolopyridine à substitution pyrazole et indazole destinés à être utilisés en tant qu'inhibiteurs de la ghréline o-acyl transférase (goat)
KR20200116978A (ko) 2018-02-02 2020-10-13 베링거 인겔하임 인터내셔날 게엠베하 그렐린 o-아실 트랜스퍼라제(goat) 억제제로서의 벤질-치환된, (피리딘-3-일)메틸-치환된 또는 (피리딘-4-일)메틸-치환된 옥사디아졸로피리딘 유도체
SG11202006300XA (en) 2018-02-02 2020-07-29 Boehringer Ingelheim Int Heterocyclyl-substituted oxadiazolopyridine derivatives for use as ghrelin o-acyl transferase (goat) inhibitors
JP7083397B2 (ja) 2018-02-02 2022-06-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング グレリンｏ－アシルトランスフェラーゼ（ｇｏａｔ）阻害剤として使用するためのトリアゾロピリミジン誘導体
JP7434169B2 (ja) * 2018-04-10 2024-02-20 サノフィ－アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 固相からの固相結合ペプチドの切断方法
CN112996811B (zh) 2018-12-21 2022-11-22 江苏恒瑞医药股份有限公司 双特异性蛋白
TWI771669B (zh) 2019-04-26 2022-07-21 美商美國禮來大藥廠 製備穩定胜肽調配物之方法
CN114641303A (zh) 2019-11-11 2022-06-17 勃林格殷格翰国际有限公司 Npy2受体激动剂
EP4192853A1 (fr) 2020-08-07 2023-06-14 Boehringer Ingelheim International GmbH Agonistes du récepteur npy2 solubles

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ202757A (en) 1981-12-23 1985-11-08 Novo Industri As Peptides and medicaments
PL192359B1 (pl) 1996-08-30 2006-10-31 Novo Nordisk As Pochodna GLP-1(7-37) lub analogu GLP-1(7-37), środek farmaceutyczny oraz zastosowanie pochodnej GLP-1(7-37) lub analogu GLP-1(7-37)
AU724326B2 (en) 1996-09-09 2000-09-14 Zealand Pharmaceuticals A/S Peptide prodrugs containing an alpha-hydroxyacid linker
WO1998011125A1 (fr) 1996-09-09 1998-03-19 Zealand Pharmaceuticals A/S Amelioration apportee a une synthese de peptides en phase solide et agent utilise dans ladite synthese
EP1066314B1 (fr) 1997-11-14 2007-12-26 Amylin Pharmaceuticals, Inc. Nouveaux composes agonistes de l'exendine
IL138214A0 (en) 1998-03-09 2001-10-31 Zealand Pharmaceuticals As Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
WO2000034331A2 (fr) 1998-12-07 2000-06-15 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Analogues du glp-1
US6451987B1 (en) 1999-03-15 2002-09-17 Novo Nordisk A/S Ion exchange chromatography of proteins and peptides
RU2001128068A (ru) 1999-03-17 2004-02-20 Ново Нордиск А/С (DK) Способ ацилирования пептидов и новые ацилирующие агенты
EP1076066A1 (fr) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides abaissant le taux de glucose sanguin
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
WO2003053460A1 (fr) 2001-12-19 2003-07-03 Eli Lilly And Company Compositions cristallines pour reguler la glycemie
KR20040070237A (ko) 2001-12-20 2004-08-06 일라이 릴리 앤드 캄파니 연장된 작용 시간을 갖는 인슐린 분자
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
EP1620465A2 (fr) 2003-04-29 2006-02-01 Eli Lilly And Company Analogues de l'insuline ayant une action prolongee
WO2006134340A2 (fr) 2005-06-13 2006-12-21 Imperial Innovations Limited Nouveaux composes et leurs effets sur le comportement alimentaire
US20090202497A1 (en) 2005-08-23 2009-08-13 The General Hospital Corporation Use of glp-1, glp-1 derivatives or glp-1 fragments for skin regeneration, stimulation of hair growth, or treatment of diabetes
CA2628241C (fr) * 2005-11-07 2016-02-02 Indiana University Research And Technology Corporation Analogues de glucagon a solubilite et a stabilite physiologiques ameliorees
WO2007081824A2 (fr) 2006-01-06 2007-07-19 Case Western Reserve University Protéines résistantes à la fibrillation
CA2638800A1 (fr) 2006-02-22 2007-09-07 Merck & Co., Inc. Derives d'oxyntomoduline
ES2673822T3 (es) 2006-07-18 2018-06-25 Sanofi Anticuerpo antagonista contra EphA2 para el tratamiento de cáncer
WO2008043033A2 (fr) 2006-10-04 2008-04-10 Case Western Reserve University Insuline et analogues de l'insuline résistants à la fibrillation
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
KR20150116465A (ko) 2007-02-15 2015-10-15 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 글루카곤/ｇｌｐ-1 수용체 공동-항진물질
DK2158214T3 (da) 2007-06-15 2011-12-05 Zealand Pharma As Glukagonanaloger
EP2025684A1 (fr) 2007-08-15 2009-02-18 Zealand Pharma A/S Analogues du glucagon
NZ603812A (en) 2007-11-20 2014-06-27 Ambrx Inc Modified insulin polypeptides and their uses
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
KR20100111683A (ko) 2008-01-09 2010-10-15 사노피-아벤티스 도이칠란트 게엠베하 극히 지연된 시간-작용 프로필을 갖는 신규 인슐린 유도체
CA2711749A1 (fr) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Nouveaux derives d'insuline a profil temporel/d'action extremement retarde
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
US8993516B2 (en) 2008-04-14 2015-03-31 Case Western Reserve University Meal-time insulin analogues of enhanced stability
WO2009132129A2 (fr) 2008-04-22 2009-10-29 Case Western Reserve University Analogues de l’insuline spécifiques à l’isoforme
TWI451876B (zh) 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
NZ589847A (en) 2008-06-17 2013-01-25 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
JP5753779B2 (ja) 2008-06-17 2015-07-22 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 生理学的ｐＨの緩衝液中で向上した溶解性及び安定性を示すグルカゴン類縁体
PL219335B1 (pl) 2008-07-04 2015-04-30 Inst Biotechnologii I Antybiotyków Pochodna insuliny lub jej farmaceutycznie dopuszczalna sól, jej zastosowanie oraz zawierająca ją kompozycja farmaceutyczna
AU2009276346B2 (en) 2008-07-31 2014-07-03 Case Western Reserve University Halogen-stabilized insulin
CN102292347A (zh) 2008-12-15 2011-12-21 西兰制药公司 胰高血糖素类似物
WO2010070255A1 (fr) 2008-12-15 2010-06-24 Zealand Pharma A/S Analogues du glucagon
JP5635531B2 (ja) 2008-12-15 2014-12-03 ジーランド ファーマ アクティーゼルスカブ グルカゴン類似体
WO2010080606A1 (fr) 2008-12-19 2010-07-15 Indiana University Research And Technology Corporation Analogues d'insuline
AU2009335715B2 (en) 2008-12-19 2016-09-15 Indiana University Research And Technology Corporation Amide-based insulin prodrugs
CN101519446A (zh) 2009-03-31 2009-09-02 上海一就生物医药有限公司 一种重组人胰岛素及其类似物的制备方法
ME02220B (me) 2009-07-13 2016-02-20 Zealand Pharma As Analozi acilovanog glukagona
EP2525809B1 (fr) 2010-01-20 2016-08-03 Zealand Pharma A/S Glucagon-glp1 agonistes doubles pour le traitement des maladies cardiaques
UY33462A (es) 2010-06-23 2012-01-31 Zealand Pharma As Analogos de glucagon
BR112012033225A2 (pt) 2010-06-24 2017-06-20 Zealand Pharma As análogos do glucagon
MA34913B1 (fr) 2011-01-20 2014-02-01 Zealand Pharma As Combinaison d'analogues du glucagon acylé à des analogues d'insuline

Also Published As

Publication number Publication date
MY160219A (en) 2017-02-28
TN2011000295A1 (en) 2012-12-17
CN102282167A (zh) 2011-12-14
EP2370459A1 (fr) 2011-10-05
EP2799447A3 (fr) 2014-12-31
AP2011005774A0 (en) 2011-06-30
EA020537B1 (ru) 2014-11-28
EA201190047A1 (ru) 2012-02-28
CA2747109A1 (fr) 2010-06-24
US20110286982A1 (en) 2011-11-24
WO2010070251A1 (fr) 2010-06-24
JP5635529B2 (ja) 2014-12-03
BRPI0823378A2 (pt) 2019-09-24
KR20110126589A (ko) 2011-11-23
US8685919B2 (en) 2014-04-01
EP2799447A2 (fr) 2014-11-05
US20150080295A1 (en) 2015-03-19
IL213477A0 (en) 2011-07-31
KR20150116912A (ko) 2015-10-16
UA104605C2 (uk) 2014-02-25
HK1203531A1 (en) 2015-10-30
AU2008365555B2 (en) 2016-01-14
EP2799447B1 (fr) 2016-11-23
MX2011006313A (es) 2011-09-27
CN102282167B (zh) 2014-08-13
AU2008365555A1 (en) 2011-07-21
SG172170A1 (en) 2011-07-28
JP2012511899A (ja) 2012-05-31

Similar Documents

Publication Publication Date Title
MA32970B1 (fr) Analogues du glucagon
MA33517B1 (fr) Analogues acylés du glucagon
NZ593813A (en) Glucagon analogues
MX2011006320A (es) Analogos de glucagon.
MX2011006314A (es) Analogos de glucagon.
TN2012000560A1 (en) Glucagon analogues
WO2010008831A3 (fr) Composés et procédés pour moduler les récepteurs couplés à la protéine g
WO2008024302A8 (fr) Composés pour le traitement de troubles prolifératifs
WO2008097835A3 (fr) Compositions et procédés de traitement de troubles métaboliques
WO2009133573A3 (fr) Formulation homéopathique
WO2010080769A3 (fr) Procédés et compositions chimiothérapeutiques
WO2010003127A3 (fr) Antagonistes des récepteurs de la prostaglandine d<sb>2</sb>
MA34850B1 (fr) Composition granulaire hydro-dispersible
WO2009140642A3 (fr) Antagonistes tricycliques de récepteurs de prostaglandine d<sb>2</sb>
EA201001329A1 (ru) Соединения и композиции в качестве модуляторов активности gpr119
WO2006084176A3 (fr) Composes et compositions utilises comme modulateurs de ppar
EP2133091A3 (fr) Compositions renfermant des assemblages supramoléculaires pour le traitement du diabète
WO2007051062A3 (fr) Dihydropyridines substituees et leurs methodes d'utilisation
MX2007010560A (es) Roflumilast para el tratamiento de diabetes mellitus.
WO2009145989A3 (fr) Antagonistes d’aminoalkylphényle de récepteurs de prostaglandine d<sb>2</sb>
WO2011008823A3 (fr) Administration non covalente médiée par peptide d'agents actifs à travers la barrière hémato-encéphalique
WO2007030761A3 (fr) 1,4-diamines acycliques et leurs utilisations
WO2009071689A3 (fr) Dérivés d'oxindole substitués par halogène en position 5 et leur utilisation pour traiter des maladies liées à la vasopressine
WO2006080549A3 (fr) Procede et composition de traitement de troubles du systeme nerveux central
WO2006042745A3 (fr) Analogues de peptides modifies chimiquement